Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study

ConclusionsWe developed a ddPCR assay to quantify the T790M mutation in plasma. Quantification of longitudinal plasma T790M mutation may allow noninvasive assessment of drug resistance and guide follow-up treatment in TKI-treated patients with NSCLC.Trial RegistrationClinical Trials.gov identifier: NCT02804100.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research